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Abstract
Background
Air pollution damages health by promoting the onset of some non-communicable diseases
(NCDs), putting additional strain on the National Health Service (NHS) and social care. This
study quantifies the total health and related NHS and social care cost burden due to fine par-
ticulate matter (PM2.5) and nitrogen dioxide (NO2) in England.
Method and findings
Air pollutant concentration surfaces from land use regression models and cost data from hos-
pital admissions data and a literature review were fed into a microsimulation model, that was
run from 2015 to 2035. Different scenarios were modelled: (1) baseline ‘no change’ scenario;
(2) individuals’ pollutant exposure is reduced to natural (non-anthropogenic) levels to com-
pute the disease cases attributable to PM2.5 and NO2; (3) PM2.5 and NO2 concentrations
reduced by 1 ȝg/m3; and (4) NO2 annual European Union limit values reached (40 ȝg/m3).
For the 18 years after baseline, the total cumulative cost to the NHS and social care is esti-
mated at £5.37 billion for PM2.5 and NO2 combined, rising to £18.57 billion when costs for
diseases for which there is less robust evidence are included. These costs are due to the
cumulative incidence of air-pollution-related NCDs, such as 348,878 coronary heart disease
cases estimated to be attributable to PM2.5 and 573,363 diabetes cases estimated to be
attributable to NO2 by 2035. Findings from modelling studies are limited by the conceptual
model, assumptions, and the availability and quality of input data.
Conclusions
Approximately 2.5 million cases of NCDs attributable to air pollution are predicted by 2035 if
PM2.5 and NO2 stay at current levels, making air pollution an important public health priority.
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002602 July 10, 2018 1 / 16
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In future work, the modelling framework should be updated to include multi-pollutant expo-
sure–response functions, as well as to disaggregate results by socioeconomic status.
Author summary
Why was this study done?
• Air pollution is the leading environmental cause of early death—contributing to the
equivalent of 5% of all deaths globally and an estimated 40,000 premature deaths each
year in the UK. Air pollution is also responsible for a substantial amount of morbidity,
causing short- and long-term health effects, as well as being a significant contributor to
health inequalities.
• Tackling air pollution will improve both the environment and public health. In the new
National Institute for Health and Care Excellence/Public Health England air pollution
guidance, local authorities are urged to consider a range of effective interventions that
promote low or zero emission areas.
• Knowing the local impact of air pollution on health and related healthcare costs over
time is important for future policy and resource planning and to target mitigation mea-
sures and public health campaigns.
What did the researchers do and find?
• This study used a dynamic microsimulation model to predict the future health and eco-
nomic impact of the air pollutants PM2.5 and NO2 to the year 2035. This microsimula-
tion examined data on air pollution exposure by age and sex, making use of disease and
population data collected from the literature and from publicly available databases. The
microsimulation method is an advanced method for modelling chronic diseases because
of its capacity to simulate entire populations at an individual level over a lifetime.
• Between 2017 and 2025, the total cost to the NHS and social care of air pollution for dis-
eases for which there is more robust evidence for an association is estimated to be £5.56
billion, corresponding to 1.15 million new cases of disease.
What do these findings mean?
• This is the first time to our knowledge that the healthcare costs of air pollution have
been estimated in England. The microsimulation tool provides estimates of the preva-
lence of disease and related NHS and social care costs due to air pollution. These esti-
mates are important and useful statistics that highlight the burden of air pollution to the
healthcare system and quantify the health and related NHS and social care cost savings
under different scenarios compared to a ‘do nothing’ scenario.
• The impacts of air pollution and the action required to address them are highly relevant
to local government priorities: health, housing, transport, education, local economies,
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greenspace, and quality of life. Local authorities have long had specific legal air quality
powers to tackle air pollution locally where there is evidence from either the local or
national assessment regimes that it exceeds legal limits. Alongside these specific obliga-
tions, strategic decisions on transport, planning, and public health taken by local gov-
ernments all contribute to the quality of the air that people breathe in local
communities.
• The UK Government will publish a final clean air strategy by the end of the year. This
strategy will set out the range of actions the government will take in the coming years to
tackle emissions of 5 key pollutants from a wide range of sources. There will be a need
to continually improve our understanding of the important health, environmental, and
economic consequences of air pollution in order to deliver an ambitious programme of
actions.
Introduction
Air pollution is a major public health concern with a high burden of disease. Exposure to fine
particulate matter (PM2.5) and nitrogen dioxide (NO2) increases the risk of non-communica-
ble diseases (NCDs) such as cardiovascular disease, respiratory disease, and lung cancer [1–3],
as well as exacerbating existing conditions such as asthma and chronic obstructive pulmonary
disease (COPD). These chronic conditions are expensive to treat and put unnecessary strain
on an already overworked healthcare system. Little is known about the extent of the attribut-
able cost of these diseases to air pollution, now and into the future. Understanding the extent
and magnitude of air pollution’s impact on long-term health is important for future National
Health Service (NHS) budget allocation, priority setting, and policy planning.
In light of this, and in response to the UK Parliament Environmental Audit Committee’s
conclusion [4] that ‘the Government must. . .urgently quantify the impact on morbidity and
the cost to the NHS of poor air quality’, this study developed a modelling framework to mone-
tise the present and future morbidity attributable to long-term exposure to PM2.5 and NO2
from outdoor sources in terms of primary care visits, prescriptions, secondary care (inpatient
and outpatient) visits, and social care. Social care is defined here as state-funded out-of-hospi-
tal care provided in the community and at a patient’s home with the primary aim of reducing
or managing the deterioration in health status for people with a degree of long-term depen-
dency, helping them with activities of daily living, and assisting them to live independently. In
estimating the health and economic burden of air pollution, we build an economic case for
investing in preventative interventions.
Using a microsimulation model, the population of England was simulated, and the number
of new air-pollution-related disease cases and resultant costs to the NHS and social care from
exposure to PM2.5 and NO2 were estimated from 2017 to 2035, as a total and separately for var-
ious conditions, while taking into account overlaps between the 2 pollutants.
Methods
The projection and microsimulation model
We used a microsimulation model to produce longitudinal projections of air-pollution-attrib-
utable NCDs and related NHS and social care costs from 2017 to 2035. The microsimulation
method is a rigorous method for modelling and projecting the long-term health impacts of
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chronic diseases into the future. The methods applied have been described in detail before
[5,6]. Study-specific adaptations to the model are described in depth in S1 Text. We created a
virtual population of 50 million individuals in the microsimulation. Each individual was
exposed to PM2.5 and NO2 according to 2015 exposure data by age and sex (described in detail
below). The population was distributed based on 2015 demographic characteristics from the
Office for National Statistics (ONS) (S2 Text) [7]. Fifty million individuals were modelled to
enhance power and detection of low-incidence diseases. All outputs were scaled to the ONS
2015 mid-year estimates for England. The microsimulation started in 2015 since the most
recent population statistics were available from that year. However, the future scenarios were
implemented from 2017, since this was the start year of the study. Therefore, cumulative fig-
ures were calculated from 2017 onwards. Population characteristics varied over time because
of aging populations, births, and deaths. In the microsimulation, PM2.5 and NO2 were treated
as individual risk factors, which were constant over time.
Asthma, COPD, coronary heart disease, stroke, type 2 diabetes, and lung cancer were
included within the microsimulation based on estimates of associations between exposure to
the pollutants and risk of developing the diseases, which were obtained from meta-analyses of
prospective cohort studies. Low birth weight and dementia were also included, although the
evidence is less well established for these conditions and, for dementia, came from a single pro-
spective cohort study. No costs were available for low birth weight, so only the epidemiological
model outputs for this condition are reported (see S3 Text). At birth, each individual in the
microsimulation was probabilistically assigned an age- and sex-specific PM2.5 and NO2 expo-
sure (i.e., their risk factor). Then, each year, exposure levels were derived using the assumption
that the exposure percentile for an individual stays constant over time. The exposure trends
were assumed to be static over time. Each year, a simulated individual was at risk of developing
a new air-pollution-related NCD, dying from an existing NCD or from other non-air-pollu-
tion-related causes, surviving with an existing NCD, or remaining in a disease-free state.
The microsimulation also contained an economic module that produced Markov-type sim-
ulations of long-term health benefits and healthcare costs, including primary and secondary
care, medication, and social care costs. The initial cost inputs were adjusted and inflated to
2015 values with a 1.5% inflation rate. The outputs of the simulation were discounted at a 1.5%
rate [8].
The confidence limits that accompany the sets of output data represent the accuracy of the
microsimulation as opposed to the confidence of the input data itself. Confidence intervals
around the input data were not available.
Exposure data
We used outdoor air pollution concentration surfaces from land use regression (LUR) models
covering England on a 100-m grid for PM2.5 [9] and 200-m grid for NO2 [10], the highest reso-
lution map available for each pollutant. These models were developed to support epidemiolog-
ical studies and take into account both local and long-range transport sources. They have been
extensively validated against measured concentrations from the Automatic Urban and Rural
Network, which contains over 100 spatially distributed continuous measurement sites [9].
We adopted a method described in Gulliver et al. for extrapolation of the air pollution sur-
faces (from 2010 for PM2.5 and 2009 for NO2) to 2015 [10]. The method compares the differ-
ence in rural background concentrations at concomitant sites from the source year (i.e., the
year each air pollution surface was developed) and the target year (i.e., 2015) for exposure esti-
mation. These absolute differences are then applied to extrapolate (i.e., reduce) modelled con-
centrations from the source year to the target year (see S2 Text).
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Postcode centroids (x,y locations) represent the central address of all addresses sharing the
same postcode (an average of 18 households share a postcode in England). We intersected all
postcode centroids, from the collection of postcode headcount information as part of the 2011
census in England (n = 1,227,431), with the air pollution surface data to obtain PM2.5 and NO2
estimates for each postcode. We applied a difference of −1.2 μg/m3 to all PM2.5 exposure esti-
mates from the 2010 model and −2.3 μg/m3 to all NO2 exposure estimates from the 2009
model to forward extrapolate them to the 2015 context (see S2 Text). We estimated pollutant
exposures by 5-year age group and sex, by assigning each postcode to the census output area
age-sex structure from the ONS mid-year population estimates for 2015 (the most recently
available at the time of this study). We then derived exposure distributions by 5-year age group
and sex for each exposure tertile category specific to England.
We used information on the contribution to total PM2.5 from dust and sea salt from the
Atmospheric Composition Analysis Group at Dalhousie University, Canada (spatial scale
approximately 620 m × 620 m) [11], to distinguish between the anthropogenic contribution
(e.g., from combustion) and the non-anthropogenic contribution (e.g., wind-blown desert and
mineral dust and sea salt spray) [12]. This enabled us to compare each individual’s exposure at
non-anthropogenic, i.e., natural, levels to a ‘no change’ scenario where exposure stays at current
levels, in order to compute the total attributable number of new diseases caused by PM2.5. We
did not include information on non-anthropogenic NO2 estimates as these data were not read-
ily available for this study and most NO2 is from anthropogenic sources, with a very low natural,
non-anthropogenic source of air pollution that might vary over short-term periods [13].
Disease data
We collected data on incidence, prevalence, mortality, survival, and exposure–response rela-
tionships for long-term air-pollution-related diseases from the published literature and
national databases. See Table 1 and S2 Text for a summary of the references for the sources of
epidemiological data. Table 2 presents the exposure–response relationships identified for each
pollutant. All of these diseases were modelled as chronic, lifelong terminal diseases with no
remission possible, with the exception of type 2 diabetes and low birth weight, which were con-
sidered non-terminal. Where epidemiological parameters were not available, for instance sur-
vival rates for stroke, we computed the parameters from other sources of data using a method
adapted from the World Health Organization equations from the DISMOD II tool.
While some exposure–disease relationships have been reviewed and quantified by the UK
Committee on the Medical Effects of Air Pollution (COMEAP), others have been extracted
from the peer-reviewed literature [2,25], and serve as the current best estimate as to what the
true exposure–response relationship is. Therefore, the strength of the association with air pol-
lution varied for each disease. Specifically, the evidence linking air pollution to dementia has
recently emerged; therefore, we interpret these findings with more caution. Those diseases
with robust evidence of a causal relationship are highlighted in grey in Table 2. Those diseases
where evidence is just associative and/or where evidence is emerging are not highlighted.
Exposure–response estimates for NO2 were adjusted and reduced by 60% to take account
of overlaps in risks with other pollutants including PM2.5, as advised and described by
COMEAP [26]. See Table 2 for the exposure–response relationships used, and S2 Text for the
sources and methods for their selection and adjustment.
Cost data
Four different categories of costs were included: primary care, prescription, secondary care
(inpatient and outpatient), and social care costs.
Modelling the costs of air pollution to the NHS and social care
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Table 1. Summary of disease statistics used in the model.
Disease Incidence Prevalence Mortality Survival
Asthma BLF asthma statistics [14] BLF asthma statistics [14] ONS death registration summary
statistics, England andWales, 2015
[15]
Computed from prevalence and
mortality
COPD Computed from prevalence and
mortality
PHE modelled estimates, 2008
[16]
ONS death registration summary
statistics, England andWales, 2015
[15]
Computed from prevalence and
mortality
CHD Smolina et al. corrected data on
incidence and mortality in 2013 [17]
BHF cardiovascular disease
statistics, 2014 [18]
ONS death registration summary
statistics, England andWales, 2015
[15]
Computed from prevalence and
mortality
Diabetes Personal communication with Dr Craig
Curry from Cardiff University
National Diabetes Audit 2015–
2016 [19]
Non-terminal Non-terminal
Stroke BHF stroke statistics, 2009 [20] BHF cardiovascular disease
statistics, 2014 [18]
ONS death registration summary
statistics, England andWales, 2015
[15]
Computed from prevalence and
mortality
Dementia Computed from prevalence and
mortality
Alzheimer’s Society Dementia
UK report, 2014 [21]
ONS death registration summary
statistics, England andWales, 2015
[15]
Computed from prevalence and
mortality
Low birth
weight
ONS birth characteristics, 2015 Considered equivalent to
incidence
Non-terminal Non-terminal
Lung cancer CRUK, 2012–2014 [22] Not required in model as
model uses incidence
CRUK, 2012–2014 [22] 1, 5 year: ONS, 2010–2014 [23];
10 year: ONS, 2008–2012 [24]
BHF, British Heart Foundation; BLF, British Lung Foundation; CHD, coronary heart disease; COPD, and chronic obstructive pulmonary disease; CRUK, Cancer
Research UK; ONS, Office for National Statistics; PHE, Public Health England.
https://doi.org/10.1371/journal.pmed.1002602.t001
Table 2. Exposure–response relationships identified for each disease by pollutant.
Outcome PM2.5 per 10 μg/m
3 (95% CI) NO2 per 10 μg/m
3 (95% CI)
Respiratory outcomes
Asthma (children6 years) Not available OR 1.08 (1.01 to 1.12)
Asthma (children>6 years) OR 1.48 (1.22 to 1.97) OR 1.03 (1.00 to 1.06)
Asthma (adults) Not available OR 1.04 (1.00 to 1.08)
COPD/chronic bronchitis (adults) OR 1.49 (1.03 to 2.14) Not available
Cardiovascular outcomes
CHD (adults) HR 1.41 (1.00 to 2.01) Not available
Stroke (adults) HR 1.13 (1.04 to 1.23) Not available
Diabetes (adults) RR 1.10 (1.02 to 1.18) RR 1.05 (1.02 to 1.07)
Cancer and other outcomes
Lung cancer (adults) RR 1.09 (1.04 to 1.14) RR 1.02 (1.00 to 1.03)
Dementia (adults) Not available HR 1.01 (1.01 to 1.03)
Low birth weight† OR 1.39 (1.12 to 1.77) OR 1.04 (1.00 to 1.07)
While confidence intervals are presented here, the microsimulation input only includes the central point estimates.
Figures highlighted in grey represent evidence of a strong causal link.
Reduced by 60% from the published values as per UK Committee on the Medical Effects of Air Pollution
recommendations.
†Modelled as associated with a woman who gives birth, see S2 Text.
CHD, coronary heart disease; COPD, and chronic obstructive pulmonary disease; HR, hazard ratio; OR, odds ratio;
RR, relative risk.
https://doi.org/10.1371/journal.pmed.1002602.t002
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In order to derive the NHS costs associated with each health condition, we used 2 different
sources: published literature and the Hospital Episode Statistics (HES) dataset. Inpatient costs
for each disease were estimated using HES, which captures actual healthcare utilisation in
NHS hospitals. We adopted a conservative approach and selected only the HES episodes in
2015 for which the main diagnosis corresponded to one of the ICD-10 codes of interest. ICD-
10 codes selected for the analysis were as follows: I20–I25 (coronary heart disease); E10, E11,
O24.4 (type 2 diabetes); J40–J44 (COPD); C34 (lung cancer); and I60–I63 (stroke). Dementia
was not analysed using HES as HES does not include specialised institutions, and we therefore
relied entirely on the literature. We then matched each episode based on its NHS Healthcare
Resource Group (HRG) to the tariff at which it was reimbursed, and used the NHSMarket
Forces Factor to account for regional differences in the cost of land, capital, and labour. We
estimated an average episode cost per health condition, and multiplied the number of yearly
diagnosed cases by the estimated average cost to account for errors in HRG reporting that did
not allow a direct match to a tariff.
When healthcare utilisation data were not available, we relied on literature providing esti-
mates of health and social care costs associated with the conditions of interest. We conducted
a literature review and selected studies based on robust and transparent methods. The relevant
literature was identified using PubMed and MeSH terms, or Google when no indexed publica-
tions reported the cost data of interest. S3 Text describes the costs extracted from the literature
in more detail. When costs were based on UK-wide or Scottish figures, costs were adjusted for
the England population.
There was a large variation in the definition of social care in the literature. This is due to the
lack of available data and the need to rely on some proxy measures, the absence of a clear defi-
nition of what counts as social care, and a lack of clear distinction between privately and pub-
licly funded care. Social care costs usually capture costs related to informal care that is funded
publicly.
The microsimulation model uses cost per case or cost per death to calculate the total health
and social care costs incurred due to the prevalence of disease.
Table 3 provides the cost per case or cost per death for each disease used in the microsimu-
lation model by type of care. These costs were adjusted for inflation in 2015 using the Hospital
and Community Health Services (HCHS) inflation index to match the year of population data
in the model (HCHS pay and price inflation is a weighted average of 2 separate inflation indi-
ces, the Pay Cost Index and the Health Service Cost Index). These inflated total costs were
then divided by the study country’s disease prevalence in 2015 in order to have an average
prevalence cost per case.
Table 3. Cost based on total prevalence of each disease, expressed in British pounds per prevalence case per year.
Disease Cost (British pounds per case) by type of care
Primary care Secondary care Medication Social care
Asthma 21.28 27.02 87.57 0.50
Chronic obstructive pulmonary disease 400.43 587.48 126.79 85.30
Coronary heart disease 71.57 1,460.46 818.60 109.70
Stroke 36.45 722.84 504.10 76.05
Diabetes 375.00 536.75 276.88 601.56
Lung cancer 51.73 466.63 35.10 89.38
Dementia 430.62 197.24 310.24 6,174.47
Indicates cost per death for palliative care.
https://doi.org/10.1371/journal.pmed.1002602.t003
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Scenarios
Different scenarios were run within the microsimulation:
1. Baseline ‘no change’ scenario, where PM2.5 and NO2 exposure stays at 2015 levels.
2. Each individual’s PM2.5 and NO2 exposure is reduced to natural (non-anthropogenic
sources) levels and compared to the no-change scenario, where exposure stays at current
levels. This enables the total attributable number of new diseases caused by PM2.5 or NO2
pollution to be quantified. Natural (non-anthropogenic) sources of PM2.5 arise from natural
sources, e.g., mineral dust and sea-salt.
3. Each individual’s PM2.5 and NO2 exposure is reduced by 1 μg/m
3 in 2017 only and is com-
pared to the no-change scenario, where exposure stays at current levels.
4. Each individual’s NO2 exposure is reduced to meet the EU limit value for NO2 (annual
average of 40 μg/m3) and is compared to the no-change scenario, where exposure stays at
current levels. This scenario was not run for PM2.5 because EU limit values (annual average
of 25 μg/m3) have been met in England.
Results
Disease cases and costs attributable to PM2.5 and NO2
Table 4 and Fig 1 provide a summary of the total disease cases and costs attributable to PM2.5
and NO2. These costs were based on both the total costs of the stronger and weaker evidence
combined. In 2017, the attributable cases of disease due to PM2.5 were estimated to be 114
Table 4. Total disease cases and costs attributable to PM2.5 and NO2.
Parameter PM2.5 NO2
2017 (95%
CI)
2017–2025 (95%
CI)
2017–2035 (95%
CI)
2017 (95%
CI)
2017–2025 (95%
CI)
2017–2035 (95%
CI)
Attributable incident cases per 100,000 114
(110 to 118)
1,062
(1,050 to 1,074)
2,248
(2,231 to 2,265)
109
(104 to 114)
943
(928 to 958)
1,933
(1,911 to 1,955)
Attributable incident cases in England 63,430
(61,276 to
65,584)
607,917
(601,661 to
614,173)
1,327,424
(1,317,505 to
1,337,343)
60,648
(58,099 to
63,197)
539,527
(531,657 to
547,397)
1,140,018
(1,128,218 to
1,151,818)
Attributable NHS and social care costs in England
(millions of British pounds)
76.10
(67.86 to
84.34)
2,814.79
(2,787.51 to
2,842.07)
9,408.71
(9,363.33 to
9,454.08)
81.06
(64.75 to
97.37)
2,749.91
(2,695.16 to
2,804.66)
9,159.22
(9,066.51 to
9,251.93)
Primary care costs 10.45
(7.86 to
13.04)
332.02
(323.43 to
340.61)
1,070.37
(1,056.10 to
1,084.64)
12.61
(9.91 to
15.31)
469.87
(460.92 to
478.82)
1,660.39
(1,645.51 to
1,675.27)
Secondary care costs 36.83
(30.99 to
42.67)
1,368.70
(1,349.36 to
1,388.04)
4,537.67
(4,505.49 to
4,569.85)
17.09
(13.47 to
20.71)
642.75
(630.79 to
654.71)
2,302.76
(2,282.94 to
2,322.58)
Medication costs 18.81
(15.52 to
22.10)
718.53
(707.65 to
729.41)
2,425.98
(2,407.87 to
2,444.09)
10.95
(8.86 to
13.04)
399.80
(392.88 to
406.72)
1,424.00
(1,412.52 to
1,435.48)
Social care costs 10.01
(5.99 to
14.03)
395.54
(382.19 to
408.89)
1,374.69
(1,352.51 to
1,396.87)
40.41
(24.88 to
55.94)
1,237.49
(1,185.27 to
1,289.71)
3,772.07
(3,683.48 to
3,860.66)
Scaling to the population of England may lead to rounding discrepancies between cases and cases avoided.
NHS, National Health Service.
https://doi.org/10.1371/journal.pmed.1002602.t004
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(95% CI 110 to 118) per 100,000, which scales to 63,430 (95% CI 61,276 to 65,584) cases in the
total population of England, at a cost of £71.10 (95% CI 67.9 to 84.3) million to the NHS and
social care. Cumulatively, by 2025 and 2035, we predicted a total of 607,917 (95% CI 601,661
to 614,173) and 1,327,424 (95% CI 1,317,505 to 1,337,343) disease cases attributable to PM2.5,
costing the NHS and social care £2.81 (95% CI 2.79 to 2.84) billion and £9.41 (95% CI 9.36 to
9.45) billion, respectively. The largest contribution of cost came from secondary care: £36.8
(95% CI 31.0 to 42.7) million in 2017, £1.37 (95% CI 1.35 to 1.39) billion by 2025, and £4.54
(95% CI 4.51 to 4.57) billion by 2035.
In 2017, the attributable cases of disease due to NO2 were estimated to be 109 (95% CI 104
to 114) per 100,000, which scales to 60,648 (95% CI 58,099 to 63,197) cases in England, at a
cost of £81.06 (95% CI 64.75 to 97.37) million to the NHS and social care. Cumulatively, by
2025 and 2035, we predicted a total of 539,527 (95% CI 531,657 to 547,397) and 1,140,018
(95% CI 1,128,218 to 1,151,818) disease cases attributable to air pollution, costing the NHS
and social care £2.75 (95% CI 2.70 to 2.80) billion and £9.16 (95% CI 9.07 to 9.25) billion,
respectively. The largest contributor to the costs came from social care, with £1.24 (95% CI
1.19 to 1.29) billion and £3.77 (95% CI 3.68 to 3.86) billion attributable to NO2 by 2025 and
2035, respectively. Diseases and costs attributable to PM2.5 and NO2 by disease and cost
parameter are presented in S4 Text.
Fig 1. Costs attributable to PM2.5 and NO2 by 2035 for each cost parameter. The confidence limits that accompany the sets of output data represent
the accuracy of the microsimulation as opposed to the confidence of the input data itself. Confidence intervals around the input data were not available.
https://doi.org/10.1371/journal.pmed.1002602.g001
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Disease cases and costs avoided due to each scenario
Table 5 presents the cumulative incidence of cases and cumulative costs avoided due to a
1-year 1-μg/m3 reduction in each pollutant relative to the no-change baseline, and the disease
cases and costs avoided if EU limit values were met for NO2 relative to baseline. Reducing
Table 5. Summary of cumulative incidence of cases avoided and cumulative costs avoided in England for each scenario relative to baseline for PM2.5 and NO2, by
period.
Scenario Parameter PM2.5 NO2
2017 (95%
CI)
2017–2025
(95% CI)
2017–2035 (95%
CI)
2017 (95%
CI)
2017–2025
(95% CI)
2017–2035 (95%
CI)
Baseline Cumulative incidence of cases 644,873
(643,114 to
646,632)
6,119,754
(6,114,646 to
6,124,862)
13,654,072
(13,645,973 to
13,662,171)
661,566
(659,721 to
663,411)
6,215,963
(6,210,268 to
6,221,658)
13,855,589
(13,847,049 to
13,864,129)
1-μg/m3 reduction in
PM2.5 and NO2
Cumulative incidence of cases 636,526
(634,767 to
638,285)
6,033,265
(6,028,157 to
6,038,373)
13,465,656
(13,457,557 to
13,473,755)
659,896
(658,051 to
661,741)
6,198,788
(6,193,093 to
6,204,483)
13,822,000
(13,813,460 to
13,830,540)
Cumulative incidence of cases
avoided (relative to baseline)
8,345
(6,191 to
10,499)
86,483
(80,227 to
92,739)
188,415
(178,496 to
198,334)
1,669
(−880 to
4,218)
17,173
(9,303 to
19,866)
33,589
(21,789 to
36,435)
Total cost avoided relative to
baseline (millions of British
pounds)
11.6
(3.4 to 19.8)
408.3
(380.8 to 435.8)
1,424.2
(1,378.3 to
1,470.1)
4.09
(−12.24 to
20.42)
108.71
(53.73 to
163.69)
353.33
(260.16 to 446.5)
Primary care cost avoided 1.59
(−1 to 4.18)
50.27
(41.64 to 58.9)
167.16
(152.8 to 181.52)
0.69
(−2.01 to
3.39)
19.89
(10.89 to 28.89)
65.63
(50.61 to 80.65)
Secondary care cost avoided 5.56
(−0.31 to
11.42)
196.62
(177.09 to
216.15)
683.71
(651 to 716.42)
0.97
(−2.65 to
4.59)
27.94
(15.91 to 39.97)
92.1
(72.08 to 112.12)
Medication cost avoided 2.91
(−0.38 to 6.2)
102.95
(91.97 to
113.93)1
362.59
(344.2 to 380.98)
0.56
(−1.53 to
2.65)
16.07
(9.12 to 23.02)
53.05
(41.47 to 64.63)
Social care cost avoided 1.51
(−2.51 to
5.53)
58.48
(45.1 to 71.86)
210.73
(188.45 to
233.01)
1.87
(−13.68 to
17.42)
44.81
(−7.62 to 97.24)
142.55
(53.55 to 231.55)
EU limit values met Cumulative incidence of cases Not applicable 652,106
(650,261 to
653,951)
6,119,176
(6,113,481 to
6,124,871)
13,630,127
(13,621,587 to
13,638,667)
Cumulative incidence of cases
avoided (relative to baseline)
9,458
(6,909 to
12,007)
96,786
(88,916 to
104,656)
225,465
(213,665 to
237,265)
Total cost avoided relative to
baseline (millions of British
pounds)
Not applicable 12.92
(−3.41 to
29.25)
442.81
(387.84 to
497.78)
1,692.87
(1,599.75 to
1,785.99)
Primary care cost avoided 2.34
(−0.36 to
5.04)
83.19
(74.2 to 92.18)
324.1
(309.11 to
339.09)
Secondary care cost avoided 3.25
(−0.37 to
6.87)
116.9
(104.88 to
128.92)
456.06
(436.08 to
476.04)
Medication cost avoided 2.02
(−0.07 to
4.11)
71.7
(64.75 to 78.65)
280.19
(268.63 to
291.75)
Social care cost avoided 5.31
(−10.24 to
20.86)
171.02
(118.6 to
223.44)
632.52
(543.56 to
721.48)
Scaling to the population of England may lead to rounding discrepancies between cases and costs avoided.
All costs are in millions of British pounds and are for the total population of England.
https://doi.org/10.1371/journal.pmed.1002602.t005
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PM2.5 by 1 μg/m
3 was estimated to reduce the air-pollution-related disease burden by 86,483
(95% CI 80,227 to 92,739) cases by 2025, and 188,415 (95% CI 178,496 to 198,334) cases by
2035. Reducing NO2 by 1 μg/m
3 was estimated to reduce the air-pollution-related disease bur-
den by 17,173 (95% CI 9,303 to 19,866) cases by 2025, and 33,589 (95% CI 21,789 to 36,435)
cases by 2035. These 1-μg/m3 reductions in population exposure to PM2.5 and NO2 would
result in £1.42 (95% CI 1.38 to 1.47) billion and £353.3 (95% CI 260.2 to 446.5) million
avoided, respectively, in NHS and social care costs by 2035. If England met the EU limit values
for NO2, it was estimated that 96,786 (95% CI 88,916 to 104,656) new cases of NO2-related dis-
eases could be avoided by 2025, and 225,465 (95% CI 213,665 to 237,265) by 2035, resulting in
£1.69 (95% CI 1.60 to 1.79) billion in health and social care costs avoided by 2035.
Discussion
In England, in 2017, PM2.5 was estimated to cost the NHS and social care £76.10 million and
NO2 was estimated to cost £81.06 million. These estimated costs are the result of 63,430 attrib-
utable incident cases of PM2.5-related diseases and 60,648 attributable incident cases of NO2-
related diseases occurring in 2017. This accounts for around 10% of the total burden of dis-
eases related to PM2.5 and around 9% of the total burden of diseases related to NO2 in 2017.
Between 2017 and 2025, the total cost to the NHS and social care of air pollution in England
was estimated to be £1.54 billion for PM2.5 and £60.81 million for NO2, increasing to £2.81 bil-
lion and £2.75 billion, respectively, when all diseases associated with these pollutants are
included (strong and weaker evidence combined). Secondary care was estimated to contribute
most to PM2.5-related costs, and social care to contribute most to NO2-related costs. This latter
finding is due to the inclusion of dementia as a disease related to NO2 (but not PM2.5), which
has a very high social care cost burden. We estimated that reducing each pollutant by 1 μg/m3
in 1 year alone would have important long-term impacts on health. Avoiding disease cases is
necessary if disease burden from air pollution is to be reduced.
This study complements existing work in a number of ways. First, using population attrib-
utable fractions, studies have found that outdoor air pollution contributes to around 40,000
premature deaths a year [27], of which 29,000 deaths are attributed to PM2.5 [28] and 11,000 to
NO2 [29,30]. Second, previous calculations costed mortality due to air pollution, estimating
between £8.5 billion and £20.2 billion a year [4], based on the ‘willingness to pay’ approach
[31]. In a complementary approach, the costs quantified in the present study represent the
costs of treating air-pollution-related diseases in the NHS and social care system. Finally, this
study also complements the work by COMEAP on the short-term impacts of NO2 on health
while extending their work on long-term impacts [32].
This study has both strengths and limitations. The use of a microsimulation model is a key
strength of this study since it models many millions of individuals over time (rather than
groups/cohorts using weighted averages, as in many studies) and records this history to deter-
mine an individual’s future risk of NCDs over the long term. However, this approach pre-
vented us from estimating the impact of short-term risks, since we were interested in annual
disease and cost outputs. Short-term peaks in air pollution are unpredictable, both temporally
and geospatially, and driven by short-term meteorology, and are therefore not straightforward
to predict based on annual averages alone. Short-term peaks may exacerbate disease and
increase secondary care, therefore causing greater NHS costs. However, it is unclear how
short-term and long-term risks overlap. Further, to analyse short-term risks, the microsimula-
tion model would require daily/monthly disease incidence data in order to initialise the micro-
simulation model population and quantify the impact of a daily spike in air pollution versus
baseline levels, data for which are not available. Further, we assumed a flat trend of pollutant
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exposure into the future. Modelling dynamic future air pollution trends would require estab-
lishing future emission and policy scenarios that could inform the model. Modelling dynamic
future trends is very complex, as illustrated byWilliams et al. [33], and often results in unin-
tended consequences (such as the promotion of diesel fuel 2 decades ago and the resultant
increase in nitrogen dioxide levels). For this study, we therefore decided against modelling
future air pollution scenarios and their related uncertainties and instead focused on scenarios
that impact the study population equally, e.g., reduction of exposure levels by 1 μg/m3. The
set-up of the microsimulation would, however, allow running specific scenarios in the future.
One limitation of the model is that it does not incorporate the effect of uncertainty of
parameters, such as the distribution of standard errors from the air pollution surfaces, which
would alter the surface and consequently the postcode estimates and resulting cost estimates.
Such uncertainty might arise from the use of ambient concentrations at place of residence (the
exposure metrics that are used for most long-term air pollution exposure studies such as those
used to derive the exposure–response functions used in this study) rather than personal expo-
sure. Similarly, the uncertainty around the exposure–response association is likely to impact
findings since effect estimates were obtained from meta-analyses of prospective longitudinal
studies, which cannot adjust for all potential confounding. The robustness of effect sizes varied
across the conditions included in the model, and some emerging exposure–response relation-
ships, i.e., for dementia and low birth weight, were obtained from a more recent, developing
evidence base. We noted the difference in robustness, and interpret the results including the
costs of dementia and low birth weight with more caution. The microsimulation was also
limited by the availability and quality of the cost data, most of which were extracted from the
literature, so they are not fully comparable. However, their different magnitudes are reliable
estimates of the cost burdens. In many cases the cost estimates represent lower bound esti-
mates of the true costs to the health and social care systems; therefore, our results are likely to
underestimate the true burden. Further work is required, potentially using primary care data-
sets to gather more up-to-date and accurate estimates of healthcare utilisation and the cost per
case of each disease. As the main objective of this project was to estimate the direct cost of pol-
lution for the NHS and social care, societal costs, such as sick leave and loss of income, were
not accounted for. Therefore, one should bear in mind that the costs reported here represent
only a share of the overall societal costs related to air pollution.
There is a lack of reporting of uncertainty on input data as only dose–response uncertain-
ties were available in the literature (S2 Text). Furthermore, correlation between the model
parameters as well as the complexity and non-linearity of the microsimulation meant that we
could only include Monte Carlo errors using a normal distribution around the outputs.
Indeed, parametric uncertainty analysis using a highly complex tool such as the UK Health
Forummicrosimulation would require running many thousands of consecutive runs, and
would require a super computer. Unfortunately, it was beyond the resources and scope of the
present project to do this.
This study had a relatively narrow focus on just PM2.5 and NO2; therefore, we are likely to
be underestimating the full impact of air pollution on the NHS and social care. Future work
should build on this model to include additional pollutants such as ozone, ultra-fine particu-
lates, and volatile organic compounds. Using COMEAP recommendations for mortality, we
adjusted NO2 dose–response relationships by 60% to take account of overlapping effects with
PM2.5 [26]. However, no guidance exists for possible adjustments for PM2.5 dose–response met-
rics. Future work might model multiple interacting pollutant risks for morbidity outcomes.
While England has reduced PM2.5 levels to below the limit values set by the EU, the magni-
tude of the number of cases and the NHS and social care costs that could potentially be avoided
by reaching EU targets for NO2makes a strong argument for policy action towards
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significantly reducing air pollution concentrations in England, to improve the quality of life of
individuals as well as reduce current pressures on the health system, specifically secondary and
social care.
This study therefore has important implications for policy makers since it makes the eco-
nomic case for investment in interventions to reduce air pollution and substantiates why expo-
sure to air pollution is a key public health priority, as highlighted in Public Health England’s
2016–2017 remit letter [34]. This study supports work that sets out actions to be taken to
reduce air pollution, namely the Department for Environment, Food and Rural Affairs’ report
on reducing roadside NO2 [35] and National Institute for Health and Care Excellence guid-
ance on traffic-related air pollution [36], and provides evidence to support third sector cam-
paigns, such as the campaign for a new Clean Air Act [37] and Client Earth’s legal action to
bring down illegal levels of pollution [38]. Measures aimed at reducing air pollution do not
just impact health but, importantly, could have many co-benefits, such as reducing road traffic
accidents [39], increasing use of public transport, supporting sustainable development [40],
mitigating climate change [41], reducing noise pollution [42], improving mental health and
well-being [43], increasing workers’ productivity [44], increasing active travel and conse-
quently physical activity [45,46], and improving the health of vulnerable groups (children, the
elderly, and socioeconomically deprived individuals) [47].
More work is needed to build on the current evidence base. The microsimulation model
presented here is a flexible and validated tool that can easily be expanded to include additional
pollutants and different populations (e.g., local authorities) and to test the long-term effective-
ness and cost-effectiveness of a range of different interventions to reduce future air-pollution-
related disease burden. The microsimulation also has the capability to include non-healthcare
costs due to disease burden (i.e., indirect costs due to lost productivity) so a wider societal
approach could be taken. Future work might also explore combining methods such as a spatial
agent-based modelling approach with a microsimulation to enable short- and long-term effects
to be modelled together or running additional pollutants in the model.
Investment in reducing air pollution is crucial if a broad range of benefits related to health,
quality of life, and the wider society are to be gained; therefore, controlling and reducing air
pollution should be a key priority for the UK Government. Effective interventions should be
implemented through collaboration between environmental, town planning, and public health
policy makers, ensuring that environmental policies consider health as a primary outcome.
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